Capstone Therapeutics Corp. (OTCPK:CAPS) announced that it has entered into a securities purchase agreement for a private placement of 13,500,000 common shares at a price of $0.075 per share for gross proceeds of $1,012,500 on July 14, 2017. The transaction will include participation from BP Peptides, LLC. The company will issue securities pursuant to exemption provided under Regulation D